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ABSTRACT
The prevalence of allergic disorders has dramatically increased over the past decade, 
particularly in developed countries. Apart from gastrointestinal disorders, neoplasia, genital 
and dermatological diseases etc., dysregulation of gut microbiota (dysbiosis) has also been 
found to be associated with increased risk of allergies. Probiotics are increasingly being 
employed to correct dysbiosis and, in turn, to modulate allergic diseases. However, several 
factors like strain variations and effector metabolites or component of them in a bacterial 
species can affect the efficacy of those as probiotics. On the other hand, host variations 
like geographical locations, food habits etc. could also affect the expected results from 
probiotic usage. Thus, there is a glaring deficiency in our approach to establish probiotics 
as an irrefutable treatment avenue for suitable disorders. In this review, we explicate on the 
reported probiotics and their effects on certain allergic diseases like atopic dermatitis, food 
allergy and asthma to establish their utility. We propose possible measures like elucidation 
of effector molecules and functional mechanisms of probiotics towards establishing 
probiotics for therapeutic use. Certain probiotics studies have led to very alarming 
outcomes which could have been precluded, had effective guidelines been in place. Thus, 
we also propose ways to secure the safety of probiotics. Overall, our efforts tend to propose 
necessary discovery and quality assurance guidelines for developing probiotics as potential 
immunomodulatory ‘Pharmabiotics.’
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INTRODUCTION
The human body harbors trillions of microbes colonized mainly in the skin and mucosal 
surface. The symbiotic co-evolution of commensal microbes with the host is evident from 
the knowledge that many of these microbial species have given up genes necessary for their 
survival in other microenvironments, while retaining genes which are beneficial for the host 
with no/little benefit to self,1 and show diversity between individuals and demographics.2 
This diversity is influenced by several factors including mode of birth,3 nutritional patterns, 
hygiene and life-style (Fig. 1). For example, urbanization and a Westernized diet have led to 
the loss of ancient commensal microbes. Alterations in microbial diversity are associated 
Allergy Asthma Immunol Res. 2018 Nov;10(6):575-590
https://doi.org/10.4168/aair.2018.10.6.575
pISSN 2092-7355·eISSN 2092-7363
Review
Received: Mar 19, 2018
Revised: May 14, 2018
Accepted: May 21, 2018
Correspondence to
Sin-Hyeog Im, PhD
Division of Integrative Biosciences and 
Biotechnology, Department of Life Sciences, 
Pohang University of Science and Technology 
(POSTECH); Academy of Immunology and 
Microbiology (AIM), Institute for Basic 
Science (IBS), 77 Cheongam-ro, Nam-gu, 
Pohang 37673, Korea.  
Tel: +82-54-279-2356
Fax: +82-54-279-0639
E-mail: iimsh@postech.ac.kr
Copyright © 2018 The Korean Academy of 
Asthma, Allergy and Clinical Immunology • 
The Korean Academy of Pediatric Allergy and 
Respiratory Disease
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Sin-Hyeog Im 
https://orcid.org/0000-0002-3173-1856
Disclosure
There are no financial or other issues that 
might lead to conflict of interest.
Garima Sharma,1,2 Sin-Hyeog Im  1,2*
1Academy of Immunology and Microbiology (AIM), Institute for Basic Science (IBS), Pohang, Korea
2 Division of Integrative Biosciences and Biotechnology, Department of Life Sciences, Pohang University of 
Science and Technology (POSTECH), Pohang, Korea
Probiotics as a Potential 
Immunomodulating Pharmabiotics in 
Allergic Diseases: Current Status and 
Future Prospects
with inflammatory conditions including allergies.4 Administration of probiotics has been 
reported to amend this dysbiotic drift by restoring the gap between the current and ancient 
symbiont communities.
The Food and Agriculture Organization (FAO)/World Health Organization (WHO) defines 
probiotics as “live microorganisms which confer a health benefit on the host when 
administered in adequate amounts.”5 Researchers and regulatory authorities, however, 
caution against the misuse of the term ‘probiotics.’ They advise that until the beneficial 
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Fig. 1. Factors affecting the diversity of intestinal microbiota. Intestinal microbial composition can vary with several factors including mode of delivery, 
age, dietary patterns, life style, use of antibiotics and probiotics. Microbial diversity can affect immune system maturation and has been linked with allergy 
incidences.4
properties of microorganisms are fully characterized, the term ‘probiotic’ should be used 
with caution. The International Scientific Association for Probiotics and Prebiotics also 
recently stated that the term probiotics does not apply to dead microorganisms, microbial 
by-products, metabolites or non-viable microbial products.5 This concept, however, 
should be revised as effector molecules can be derived from cellular components such as 
lipopolysaccharides and polysaccharides.6,7 There is increasing evidence to suggest that 
every probiotic microbial strain does not have a unique mechanism of action despite shared 
taxonomic lines.8 Advances in bioinformatics-based research and mechanistic understanding 
of probiotics' mode of action will perhaps allow some generalization to be made at the 
taxonomic level with respect to the immunological mechanism of probiotics.8
Studies in the past decade have led to a deeper understanding of the interplay between 
microbiome and the innate and adaptive immune system to guide immune tolerance and to 
alleviate allergic disease. We here attempt to review the current evidence and advancements 
in research for use of probiotics in allergic disorders. Also, as ‘Efficacy and Toxicity’ are 
interdependent characteristics of therapy, we highlight the need for improved safety regulations.
ROLE OF MICROBIOTA IN THE DEVELOPMENT OF 
IMMUNE TOLERANCE TO ALLERGENS
Primarily, the infant immune system presents type 2 helper T cell (Th2)-dominant 
phenotypes and gradually increases type 1 helper T cell (Th1) immune response to maintain 
immune homeostasis. Th2-skewed phenotype leads to higher immunoglobulin E (IgE) 
levels and mast cell activation, which in turn increases susceptibility to allergic disorders. 
The microflora plays a significant role in restoring Th1/Th2 immune responses.9 The Th2-
dominant phenotype of an infant is reproduced in germ-free (GF) mice, which exhibits higher 
susceptibility to allergic reactions. Interestingly, colonization with commensal microbes can 
reverse this phenotype, demonstrating the key role played by microbiota. Commensals also 
play a role in regulating immune cell recruitment. Neonatal exposure to microbiota prevents 
accumulation of invariant natural killer cells in the colonic lamina propria and the lungs in 
a CXCL6 chemokine-dependent manner, thereby ameliorating airway allergic responses.10 
Furthermore, loss of tolerance was reported in adults after extensive antibiotic treatment.9
Another perspective of these observations is reflected in ‘hygiene hypothesis.’ It suggests 
that reduced microbial exposure during infancy due to increased public hygiene is one of the 
primary causes of heightened susceptibility to allergies.9 This hypothesis is elegantly supported 
by a recent study in which Amish children raised in conventional farms had lower prevalence 
of allergic disease than Hutterite children raised in industrialized farms, despite similarities 
of genetic background.2 Also, house dust extracts from Amish houses inhibited ovalbumin 
(OVA)-induced allergic inflammation in mice in a MyD88 and TRIF-dependent mechanism.2 
Of note, the bacterial composition of Amish house dust was dominated by Bartonellaceae, which 
had higher endotoxin levels than Hutterite house dust. Long-term exposure to low-dose 
endotoxin or ‘farm dust’ demonstrated protective effects in house dust mite (HDM)-induced 
asthma in mice.11 Protection was mediated via activation of A20 (TNFAIP3) in airway epithelial 
cells modifying the epithelial and dendritic cells (DCs) interactions.11 Similarly, these studies 
establish the role of microbiota in influencing allergic immune reactions. In the subsequent 
part of the review, we elaborate on probiotics-based intervention of allergic diseases and 
propose changes required for the advancement of the probiotics field.
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PROBIOTICS IN ALLERGY MANAGEMENT
Inflammation is a fundamental defense response of body's immune system against foreign 
antigens; however, hypersensitivity is a host protective immune response on repeated 
exposure to specific antigens, but potentially deleterious to the host. Based on physiological 
mechanisms involved and time of response, Gell and Coombs have classified hypersensitivity 
into 4 types, types I to IV. However, the clinical manifestations of allergic reactions 
demonstrate overlap or simultaneous occurrence of humoral and cell-mediated immune 
responses making the differential diagnosis of 4 types difficult. Johansson et al.12 proposed a 
more clinically applicable classification based on involvement of IgE, excluding non-allergic 
non-immunological reactions. A general pathogenesis of an allergic response includes: 
sensitization to allergens (HDM, pollen, food, etc.), transient inflammatory response, 
increase in allergen specific IgE, and migration of effector T cells, mast cells and eosinophils 
to the site of exposure. Hyper-responsiveness is orchestrated by Th2 cells, with cytokine 
profiles dominated by interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31. Eosinophils play a major 
role in respiratory allergies by degranulation at the site of exposure causing influx of immune 
cells and tissue damage. Skin and food allergies can also be referred to as the second wave of 
allergic epidemics.
Probiotics for allergic skin disorders
Atopic dermatitis (AD) is the most common familial, chronic, recurrent and non-infectious 
inflammatory skin disease with a wide clinical spectrum. It is often associated with other 
disorders like food allergies, asthma, allergic rhinitis (AR), cardiovascular diseases and 
obesity. AD can be classified into extrinsic AD with high serum IgE or intrinsic/non-atopic AD 
with normal serum IgE levels.13 Classically, AD was considered a biphasic disease presenting 
acute and chronic stages, predominated by Th2 and Th1 responses, respectively. However, 
recent studies indicate AD is more heterogeneous — the acute phase consisting of both Th2 
(IL-4, IL5, IL-13, IL-31, and CCL-18) and Th22 (IL-22 and S-100A proteins) responses, while 
chronic stage consisting of accentuated acute phase pathways along with Th1 signatures 
(interferon [IFN]-γ, CXCL-9 and CXCL-10).13 Some findings also suggest involvement of a 
Th17 axis, particularly in Asian patients, although cytokine patterns and clinical symptoms 
like parakeratosis indicate the complication of AD with psoriasis.13 Regulatory T cells (Tregs), 
an immunoregulatory subset of T cells, have been reported to be increased in the peripheral 
blood of AD patients14 as well as in skin lesions; however, contrasting findings have reported 
functional defects in Tregs of AD patients.15
Staphylococcal aureus is the most common pathobiont found in AD lesions and shows a 
close association with AD disease severity, food allergy and enhanced IgE responses.16 
Furthermore, dysbiosis and the reduced microbial diversity of skin and intestine are 
also suggested to be associated with exacerbation of AD. Nylund et al.17 observed higher 
abundance of Clostridium clusters IV and XIVa and lower abundance of Bacteroidetes in 
18-month-old children with eczema. It is interesting to note that microbial composition 
was similar between healthy and eczema patients at 6 months of age.17 In another study, 
Abrahamsson et al.18 discovered lower Bacteroidetes diversity at 1 month of age in a Swedish 
cohort of infants who subsequently developed atopic eczema at 2 years of age. Similarly, 
lower Bacteroidetes diversity was observed in pregnant mothers of infants who eventually 
developed atopic eczema, although this was not observed in the infants themselves after 
birth.19 However, they observed depletion of Ruminococcaceae in 1 week-old infants that 
developed IgE-associated eczema, suggesting a correlation between abundance of specific 
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bacterial taxa and cytokine response to TLR ligands.19 Probiotics seem to restore the balance 
between Th1/Th2 immune responses and microbial composition in allergic patients. 
Although these studies provide compelling evidence linking microbial dysbiosis with allergic 
diseases, some other reports failed to reproduce these findings.
Pre-clinical models of AD have provided much immunological insights into AD pathogenesis. 
However, it is worth noting that existing mouse models of AD differ significantly from human 
AD. Comparison of human AD skin transcriptomes with mouse AD models revealed that 
none of them fully captured human AD.20 Interestingly, IL-23-injected mice, a conventional 
animal model for psoriasis, best represented the human AD profile, yet the similarity was 
only 37% in terms of gene expression.20
To identify specific immune-regulatory probiotic strains, we have reported an ex vivo screening 
system.21,22 In brief, individual probiotic strains were cultured with mesenteric lymph node 
cells isolated from Foxp3-reporter mice or wild type mice. End point analysis for cytokines 
or expression of Foxp3-transcription factors was done by enzyme-linked immunosorbent 
assay or flow cytometry, respectively. Based on the level of anti-inflammatory (IL-10) and 
pro-inflammatory (IL-12p70) cytokines, we selected the strains that induced IL-10high/IL-12low 
expressions. Out of several hundreds of candidate strains, we selected Bifidobacterium bifidum, 
Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus reuteri, and Streptococcus thermophiles; 
mixture of these was named IRT5.22 Administration of IRT5 suppressed the development 
and progression of experimental autoimmune uveitis,23 multiple sclerosis,24 myasthenia 
gravis,25 rheumatoid arthritis,22 age-dependent colitis26 and allergic contact hyper-sensitivity 
(unpublished data). IRT5 was also potent in suppressing a mouse model of experimental 
AD through potentiation of CD4+Foxp3+ Tregs (Table 1). 22 In general, IRT5 worked through 
phenotypic alteration in conventional DCs to a regulatory DCs (rDCs), which then induced  
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Table 1. Effect of probiotics in preclinical studies of AD in mice
References Probiotics strain/s Animal model used Observations Clinical/Histopa-thological scores
Lim et al.27 Weissella cibaria WIKIM28 DNCB induced AD in 
BALB/c mice
Reduced Th2 cytokines, generation of 
CD4+ Foxp3+ T cells and increased IL-10 
levels in mLN
Improved
Choi et al.59 Heat killed Lactobacillus brevis NS1401 House dust mice 
induced AD in Nc/
NgA mice
Reduced serum IgE, eosinophil & mast 
cell infiltration, allergen specific IgG1  
and Th1/Th2 cytokines
Improved
Shin et al.60 Lactobacillus acidophilus CBT 
LA1, Lactobacillus rhamnosus CBT 
LR5, Lactobacillus plantarum CBT 
LP3, Bifidobacterium bifidum CBT 
BF3, Bifidobacterium breve CBT 
BR3, Lactococcus lactis CBT SL6, 
Streptococcus thermophilus CBT ST3
DNCB induced AD in 
Nc/NgA mice
Generation of CD4+ Foxp3+ T cells in 
mLN, low serum IgE, IL-4 and IL-5,  
high Th1 IFN-γ, IL12p40
Improved
Kim et al.61 Lactobacillus casei, L. plantarum,  
L. rhamnosus and Bifidobacterium lactis
DNCB induced AD in 
Nc/NgA mice
Low serum IgE, IL-4 and IL-5, high Th1 
cytokines IFN-γ, IL12p40
Improved
Weise et al.62 Escherichia coli Nissle 1917 Allergen induced AD 
in BALB/c mice
Increased IFN-γ, IL-10, TGF-β and 
proportion of CD4+ Foxp3+ T cells
Improved
Won et al.28 L. plantarum CJLP133 House dust mice 
induced AD in Nc/
NgA mice
Reduced cell infiltration and Th2 
cytokines
Improved
Activation of Tregs
Kwon et al.22 IRT5 probiotic mixture:  L. acidophilus,  
L. casei, Lactobacillus reuteri,  
B. bifidum, S. thermophilus
HDM/DNCB induced 
AD in BALB/c mice
Generation of CD4+ Foxp3+ Tregs Prophylactic & therapeutic effect
Migration of Tregs to the inflamed region Suppression of ongoing  
AD progressionReduction of serum (total and allergen 
specific) IgE level, cellular infiltration 
and Th2 cytokines
AD, atopic dermatitis; DNCB, dinitrochlorobenzene; Th2, type 2 helper T cell; IL, interleukin; mLN, mesenteric lymph node; IgE, immunoglobulin E; Th1, type 1 
helper T cell; IFN, interferon.
de novo generation of induced Foxp3+-regulatory T cells (iTreg). Recently, we discovered 
another B. bifidum strain that is the most potent inducer of iTregs among all the tested 
probiotic strains. Monocolonization of the B. bifidum in GF mice induced Tregs in high 
frequencies mainly in the colon where the bacteria colonize. Furthermore, we defined cell 
surface polysaccharides as the key effector molecules involved in de novo generation of Tregs 
in a DC-dependent manner (unpublished data). Similar results were reported by Lim et al.27 
using a non-conservative bacterial species of Weissella cibaria WIKIM28 in DNCB induced 
AD mice. Administration of probiotics reduces mast cell infiltration of lesions, suppresses 
Th2 responses, and increases Treg populations in peripheral lymph nodes.27 Lactobacillus 
plantarum CJLP133 reduced skin inflammation in HDM-induced dermatitis in Nc/NgA 
mice by modulating the Th1/Th2 balance and by activating Tregs.28 These findings show 
administration of probiotics could modulate allergic responses by targeting various immune 
cells (Fig. 2).
Probiotics treatment in AD patients, however, shows inconsistent results in clinical trials  
(Table 2). Administration of L. plantarum CJLP133 improves Scoring Atopic Dermatitis 
(SCORAD) index in pediatric patients of AD by decreasing levels of IFN-γ, IL-4 and eosinophil 
counts.29 Another randomized, double-blind, placebo-controlled trial (RCT) on pediatric 
AD investigated the effect of Lactobacillus paracasei and Lactobacillus fermentum and observed 
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Fig. 2. Overview of mechanisms of action of probiotics in allergic diseases. Primary mode of action of probiotics includes restoration of Th1/Th2 cytokine 
balance13 and induction of CD4+Foxp3+ Treg38 cells. Other specific mechanisms include reduction in allergen specific IgE38,52 and increased SCFA56,57 levels. 
Probiotics also aids in constant homeostasis by maintaining intestinal epithelial integrity, increased anti-microbial production and competitively inhibiting 
survival of pathogens. 
Th2, type 2 helper T cell; Th1, type 1 helper T cell; Treg, regulatory T cell; IgE, immunoglobulin E; SCFA, short-chain fatty acid.
improvement in SCORAD scores up to 4 months after discontinuation of probiotics.30 
Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347 and L. casei CECT 9104 were 
able to reduce SCORAD index in a 12-week RCT on young Spanish patients with AD.31 A meta-
analysis of 25 RCTs suggested that administration of probiotics improved AD from 1–18 years 
of age but results for less than 1 year of age were not confirmatory.32 They also observed that a 
mixture of Lactobacillus was better than Bifidobacteria alone.32 On the other hand, recent review of 
13 RCTs on children with AD suggested no robust differences between probiotic and placebo 
treated groups.33 The beneficial effects of probiotic administration in allergic disorders are 
still questionable due to the small cohort size and heterogeneity among studies. Interestingly, 
differential efficacy may also depend on geographical or racial-genetic effects as Asian children 
(1–18 years) were responsive, while Europeans children presented no effect.33 Moreover, 
strain-specific effects have been observed. For example, Lactobacillus sakei and L. fermentum were 
effective, while L. plantarum and Lactobacillus rhamnosus GG had no effect against allergy.33
Use of probiotics for the prevention of eczema has also been explored. An RCT showed 
maternal supplementation with L. rhamnosus HN001 (HN001) starting from 35 weeks of 
gestation until 6 months of breast-feeding and infant supplementation from birth to 2 years 
of age significantly reduced the prevalence of eczema up to 6 years of age.34 On the other hand, 
Bifidobacterium animalis subsp lactis HN019 (HN019) had no significant effect on any outcome.35 
A recent meta-analysis of 6 trials, comprising 1,955 patients, suggested use of probiotics early 
in life is likely to prevent AD later in life.36 However, it is difficult to generalize the efficacy of 
probiotics in AD modulation due to considerable heterogeneity between studies.
Probiotics for allergic asthma
Although asthma is conventionally considered a Th2-type inflammatory condition, it 
has been recognized as a clinically heterogeneous disease and etiology for many of the 
asthma phenotypes are yet to be understood. Several studies have described the microbiota 
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Table 2. Effects of probiotics in clinical trials on patients with AD
References Probiotics strain/s Clinical patients Observations Clinical outcome  
(SCORAD index, clinical symptoms)
Navarro-López et al.31 Bifidobacterium lactis CECT 8145, 
Bifidobacterium longum CECT 7347, 
and Lactobacillus casei CECT 9104
Pediatric Reduced use of topical corticosteroids Improved
Wang et al.30 Lactobacillus paracasei, Lactobacillus 
fermentum and mixture
Pediatric Reduced IL-4, marginally increased 
TGF-β, IFN-γI
Improved
Niccoli et al.63 Lactobacillus salivarius LS01 Pediatric - Improved
Yang et al.64 Mix: L. casei, Lactobacillus rhamnosus, 
Lactobacillus plantarum, and B. lactis
Pediatric No change in cytokine profile No change from placebo
Inoue et al.65 Heat killed Lactobacillus acidophilus 
strain L-92
Pediatric Reduced eosinophil count,  
increased TGF-β
Improved
Wickens et al.35 L. rhamnosus HN001 Pediatric Reduced serum total IgE, Improved
Yeşilova et al.66 Mix: Bifidobacterium bifidum, L. 
acidophilus, L. casei, and L. salivarius
Pediatric Reduced IL-5, IL-6, IFN-γ and total 
serum IgE
Improved
Iemoli et al.67 Mix L. salivarius LS01 and 
Bifidobacterium breve BR03
Adults Reduced Th1/Th2 cytokines and  
Th17/Treg ratio
Improved
Han et al.29 L. plantarum CJLP133 Pediatric Reduced IL-4, IFN-γ and total 
eosinophil count
Improved
Gore et al.68 L. paracasei CNCM I-2116 or B. lactis 
CNCM I-3446
Pediatric - No change from placebo
Drago et al.69 L. salivarius LS01 Adults Reduced Th1 cytokines (IL-12, IFN-γ), 
Th1/Th2 cytokines ratio and serum IgE
Improved
Woo et al.70 Lactobacillus sakei KCTC 10755BP Pediatric Lower serum levels of CCL17 and 
CCL27
Improved
AD, atopic dermatitis; SCORAD, Scoring Atopic Dermatitis; IL, interleukin; TGF, transforming growth factor; IFN, interferon; IgE, immunoglobulin E; Th2, type 2 
helper T cell; Th1, type 1 helper T cell; Treg, regulatory T cell.
composition of the respiratory or gastrointestinal tracts associated with asthma occurrence. 
However, it is still not clear how dysbiosis affects susceptibility to asthma. Neonatal 
susceptibility to allergic airway inflammation is reversed in adult mice post development 
of an airway microbiome. Gollwitzer et al.37 observed a shift in lung microbiome from 
Gammaproteobacteria and Firmicutes to Bacteroides in the first 2 weeks of life. These changes 
were associated with PD-L1 dependent emergence of CD4+Helios−Foxp3+ Treg cells in lungs.37 
Immune modulating effects of commensals are not limited to local tissue alone; intestinal 
commensals also affect respiratory immune responses. For example, short-chain fatty acids 
(SCFAs) that are produced by commensals during fermentation of dietary fibers suppress 
allergic airway responses. Higher serum SCFA, particularly propionate, suppress induction 
of Th2 responses in the lungs by modulating DC progenitors in bone marrow in a G-protein 
coupled receptor 41-dependent manner.38 Among the SCFAs, butyrate is the most potent 
immunoregulatory metabolite. Butyrate producing mixture of Clostridia species types IV, XIVa 
and XVIII induce colonic Treg cells in mice.39 Clostridium butyricum suppressed inflammatory 
responses by inducing IL-10-producing macrophages.7 Butyrate and propionate have HDAC 
inhibitory activity, enhance histone acetylation state in the Foxp3 locus,39,40 and induce 
tolerogenic DCs to enhance Treg generation.40 Bacteria belonging to the clostridial family 
Lachnospiraceae and Ruminococcaceae are also known to ferment dietary fibers in the colon to 
produce SCFAs, thereby supporting epithelial integrity and homeostasis. However, whether 
these findings could be recapitulated in humans should be tested in clinical trials.
Therapeutic effects of probiotics in human asthmatic patients are not well established. An 
8-week RCT on children with asthma and AR treated with Lactobacilllus gasseri A5 showed a 
significant reduction in symptoms along with improvement of pulmonary function.41 Oral 
administration of L. rhamnosus GG (LGG) alleviated asthma symptoms in an OVA-sensitized 
model of mouse asthma.42 In other studies, however, probiotic treatment early in life had 
no effect in preventing asthma.43 Collectively, the current evidence does not support use of 
probiotics in prevention or treatment of asthma.
Probiotics for food allergy and food-induced anaphylaxis
Adverse reactions to foods manifest in 2 forms, food allergy and food intolerance. Food 
allergy consists of immune responses against certain foods, while food intolerance is a non-
immunological reaction. The best characterized food allergies are IgE-mediated immediate 
hypersensitivity reactions, the others being non-IgE-mediated delayed type reactions. Most 
cutaneous allergic reactions to food are IgE-mediated.44 Cross-linking of allergen-specific 
IgE antibodies to their receptor FcεRI, expressed on mast cells and basophils, results in 
the release of cellular mediators and inflammation. Food allergy can also be explained 
as failure of oral tolerance, which is usually established in infancy. Oral tolerance refers 
to immunological hypo-responsiveness towards dietary antigens and endogenous gut 
microflora. Intestinal DCs sample intestinal antigens promoting development of CD4+Foxp3+ 
Tregs. On the other hand, epithelial cells produce the inflammatory trio, thymic stromal 
lymphopoietin, IL-33 and IL-25 upon insult, activating mast cells, innate lymphoid cells 
(ILCs) and DCs to induce Th2 type immune response.45 IL-33 also up-regulates OX40L on 
DCs driving Th2 immunity.45 Oral exposure to food antigens early in life is believed to induce 
tolerogenic responses to dietary antigens leading to decreased occurrence of food allergy. A 
‘dual exposure hypothesis’ for food allergy, proposed by Lack, suggests that development of 
oral tolerance occur by oral exposure to antigen, while sensitization occurs upon cutaneous 
exposure to low-dose antigen.46 Eczema and mutations in filaggrin (a protein necessary for 
cutaneous integrity) are associated with increased risk of AD as well as food allergy.
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Intestinal microbiome can also influence development of oral tolerance and sensitization 
to food antigens. Abundance of Clostridia and Firmicutes were linked to cow's milk allergy in 
infants. Administration of LGG-supplemented casein formulas in infants with cow's milk 
allergy led to enrichment of butyrate-producing taxa accelerating tolerance acquisition. 
A 3-year RCT on a similar cohort revealed LGG supplementation reduced the risk of other 
allergic manifestations.47 In murine models of food allergy, colonization of gnotobiotic 
mice with Clostridia suppressed sensitization to food allergen. Mono-association of 
Clostridia-increased CD4+Foxp3+ Treg cell numbers and IgA production while promoting 
IL-22 production by RORγt+ ILCs and T cells in the lamina propria, thus restoring epithelial 
integrity. Certain Clostridia species were also found to suppress food allergic reactions 
therapeutically.48 In a different strategy, transfer of intestinal microbiota from food allergy-
prone mice to wild type GF mice induced food allergy phenotype.49 Similarly, food allergy-
prone IL-4 receptor alpha chain mutant mice (IL-4RαF709) showed a distinct microbial 
signature with differential abundance of Lachnospiraceae, Lactobacillaceae, Rikenallaceae and 
Porphyromonadaceae.49 Tang et al.50 evaluated the effect of probiotics as an adjuvant to oral 
immunotherapy (OIT) in children with peanut allergy. Co-administration of L. rhamnosus 
CGMCC1.3724 and peanuts led to sustained desensitization and reduced peanut-specific 
IgE levels.50 However, evidence for therapeutic and preventive effects of probiotics on food 
allergy in human subjects is still sparse. Since induction of antigen-specific oral tolerance 
requires a tolerogenic microenvironment, high IL-10-inducing probiotic strains might be 
employed for OIT to treat allergy and autoimmunity in the future.21,22
PROPHYLACTIC AND THERAPEUTIC EFFICACY OF 
PROBIOTICS TO TREAT ALLERGIC DISORDERS
As described above, although health benefits of taking probiotics have been reported in 
allergic disorders, it is still early to draw any conclusions. Prominent regulatory organizations 
like the American Academy of Pediatrics, National Institute of Allergy and Infectious 
Diseases, European Academy of Allergy and Clinical Immunology, European Society for 
Pediatric Gastroenterology, Hepatology and Nutrition and FAO of the United Nations/WHO, 
do not support the use of probiotics for primary prevention of allergic diseases.51 In 2015, 
the World Allergy Organization (WAO) applied Grading of Recommendations, Assessment, 
Development and Evaluation approach to develop evidence-based recommendations for 
using probiotics in the prevention of allergic diseases.52 Findings were reported in a systemic 
review of 29 RCTs by Cuello-Garcia et al.43 The panel observed that there is insufficient 
evidence to support recommendation to use probiotics in primary prevention of allergic 
diseases. However, they suggested the use of probiotics in pregnant/lactating women and 
infants with a family history of allergic disease. Although strain-specific activity of different 
bacterial species is recognized, no recommendations were made by the WAO regarding strain 
or dose of probiotics in light of insufficient evidence.52
SAFETY OF PROBIOTICS FOR HUMAN PATIENTS
Probiotics are generally considered safe for consumption. However, increasing evidence 
raises concern over generalizing the safety of probiotics. In 2002, a joint report released 
by WHO and FAO of the United Nations indicated that probiotics may be responsible for 4 
types of side effects: systemic infections, deleterious metabolic activities, excessive immune 
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stimulation in susceptible individuals and gene transfer.53 The ‘Probiotics in Pancreatitis Trial 
(PROPATRIA),’ a prophylactic clinical trial for acute pancreatitis in human patients, created 
a furor as large number of deaths were reported in the probiotic-treated group compared 
to control, 16% versus 6%.54 It was also reported that treatment of patients with a multi-
strain probiotic led to bowel ischemia development.54 An enquiry into the trial identified 
inadequate knowledge on the safety of probiotics used. This investigation grabbed the 
attention of the scientific community towards looking into adverse effects of probiotics. 
Lactobacillus and Bifidobacterium are generally considered safe, and therefore dominate the 
commercial formulas of probiotics. A recent investigation, however, identified Bifidobacterium 
adoloscentis as a potent inducer of IL-17, which plays pathogenic roles in inflammatory bowel 
disease (IBD) and rheumatoid arthritis.55 Although Bifidobacterium species have long been 
associated with Treg induction,22 including Bifidobacterium adolescentis,55 the current findings 
indicate that a harmless probiotic strain can be counterproductive in disease conditions. 
Tan et al.55 further tested 6 probiotic formulas containing Bifidobacterium species, 4 of which 
similarly induced Th17 cells in mice, although their effects in an autoimmune set-up were not 
confirmed. These observations warrant an investigation into the clinical safety of probiotics 
before commercialization. Some groups further argue that probiotics with medical claims 
must receive Food and Drug Administration (FDA) approval like any other drugs, including 
filing of Investigational New Drug Application (IND) and clinical trials, phases I–III. Other 
groups support the necessity of regulations, but disagree on receiving FDA approval as this 
will incur huge expenses and cause major delays in the overall research.5 We believe the 
safety of probiotics must not be overlooked; the IND application process can be modified for 
probiotics products to expedite research without adding much to the cost.
CHALLENGES AND FUTURE PERSPECTIVE IN PROBIOTIC 
RESEARCH
Advances in molecular and microbiological techniques have enabled us to perform in-depth 
research into microbial diversity found in the human commensal pool. To-date, however, 
most of the probiotic research has focused on the bacteria itself rather than the host-bacteria 
interaction. Moreover, available data omits the importance of mycobiome and virome. 
This has arisen from difficulty in processing fungal DNA, underdeveloped fungal genome 
databases, unavailability of viral 16S rRNA sequencing and inefficient bioinformatics tools. In 
our observations, commensal yeast, recognized mostly as an opportunistic pathogen, can act 
as a potent immunoregulator in inflammation and autoimmune diseases (unpublished data). 
The interaction and harmony between microbiome, mycobiome and virome can be important 
in maintaining homeostasis and offers a window for further investigation.
As more academic and clinical research groups focus on commensals, the number of 
probiotic species with health claims is increasing. However, there is no international 
consensus for the screening of these microbial species. Current screening methods focus 
on the cytokine induction ability of microbes using cell lines or ex vivo isolated peripheral 
immune cells, even though they do not represent the phenotype of intestinal cells. There is 
a need to devise high-throughput screening methods to ensure the specificity and efficacy of 
selected probiotics. Most commercially available probiotics are mixtures of bacterial strains 
with defined colony forming units (CFUs); therefore, it is also important that consumers be 
informed of the product shelf life of individual strains to ensure viability of bacteria in the 
administered dosage. A recent report also suggested the manufacturing process of probiotic 
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mixtures can affect their activity. VSL#3, a probiotic mixture made in the USA, was found 
to be beneficial in HIV-infected subjects and also IBD by reducing the 1,3 dihydroxyacetone 
(DHA) levels in feces.56 On the contrary, a similar mix made in Italy enhanced DHA levels 
leading to adverse effects.56 These findings suggest the same bacteria can have different 
functions, depending on their culture conditions. Thus, using functional markers rather 
than CFU counts might be a better readout of probiotic quality control. Moreover, as the 
composition of commensals varies among populations, efficacy of probiotics may also 
vary among populations. Hence, clinical trials should be expanded to include different 
geographical locations. With this in mind, it is advisable not to perform meta-analyses 
on pooled data when different strains of bacteria were used, since the effects can vary 
dramatically among strains.55
The majority of disease-related health claims for probiotics have been rejected due to 
lack of supportive data. Then, how can we establish probiotics as a modulator of specific 
diseases? Analysis of disease-associated markers could be a simple approach. For example, 
Roessler et al.57 explored different effects of selected probiotics in healthy and AD patients, 
and found probiotic treatment increased CD57+ NK cells in healthy subjects, but not in AD 
patients. Kim et al.58 reported that characterization of clinical phenotype of patients and 
selection of patients based on the immunological parameters (i.e., high IgE level) could 
enhance the possibility of probiotic efficacy. However, these approaches do not cover many 
important issues such as the molecular and cellular identity of the probiotic strain, full 
genome sequences and mechanisms of action in homeostatic/disease conditions. Therefore, 
application of probiotic strains in patients should not be allowed unless the safety and 
effector molecules of the probiotics are well defined. Moreover, the term “Probiotic” should 
not be generically used as some exacerbate disease under different conditions.
CONCLUSION
The current understanding of probiotics suggests their beneficial effects to prevent AD. 
However, evidence is still lacking to support the general efficacy of probiotics in the modulation 
of other allergic conditions. Valid conclusions cannot be drawn based on pooling of data 
from different probiotic strains or combinatory administrations. Thus, there is a need to 
develop international standards for study designs on probiotics to ensure uniformity across 
clinical trials. Further, there is a glaring deficiency in quality standards of probiotics which 
shall be addressed by defining genetic identity of strains and uniform production guidelines. 
Moreover, future studies are warranted to refine the effector molecules of probiotics and to 
identify their mode of action in healthy and diseased conditions. We also want to emphasize 
the need of functional markers for screening probiotics, which could serve as a standard for 
quality control toward each batch of manufactured products. Annotating genomic information 
involved in coding the functional molecules is also necessary as bacteria could lose their genetic 
information during large-scale cultures. Once the safety and efficacy of the effector molecule(s) 
are assured, application of probiotic bacteria for treating allergic disorders might be possible. 
In addition, once they show beneficial effects in clinical trials, we could call them “Probiotics.” 
Furthermore, if we can purify the effector molecules from the probiotic bacteria in large 
amounts, we may use this to treat allergy symptoms in the future (Fig. 3). Although, current 
definition excludes these products from the category ‘Probiotic,’5 we propose that microbial 
derived molecules with health benefits could be included in a separate category within 
probiotics, termed “Pharmabiotics.”
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